| Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial MJ Frigault, J Dietrich, K Gallagher, M Roschewski, JT Jordan, D Forst, ... Blood, The Journal of the American Society of Hematology 139 (15), 2306-2315, 2022 | 80 | 2022 |
| Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS) M Wehrli, K Gallagher, YB Chen, MB Leick, SL McAfee, AR El-Jawahri, ... Journal for immunotherapy of cancer 10 (1), 2022 | 66 | 2022 |
| Blockade or deletion of IFNγ reduces macrophage activation without compromising CAR T-cell function in hematologic malignancies SR Bailey, S Vatsa, RC Larson, AA Bouffard, I Scarfò, MC Kann, ... Blood Cancer Discovery 3 (2), 136-153, 2022 | 60 | 2022 |
| A phase II trial of anakinra for the prevention of CAR-T cell mediated neurotoxicity MJ Frigault, KME Gallagher, M Wehrli, B Valles, K Casey, K Lindell, ... Blood 138, 2814, 2021 | 10 | 2021 |
| Association of bridging therapy utilization with clinical outcomes in patients receiving chimeric antigen receptor (CAR) T-cell therapy PC Johnson, C Jacobson, A Yi, MR Gaballa, N Horick, DJ Rabideau, ... Journal for ImmunoTherapy of Cancer 10 (9), 2022 | 4 | 2022 |
| Tisagenlecleucel demonstrates safety, efficacy and CNS trafficking in primary CNS lymphoma MJ Frigault, J Dietrich, KME Gallagher, I Scarfò, M Roschewski, JT Jordan, ... Blood 138, 258, 2021 | 4 | 2021 |
| CAR-T Cell Therapy in Recurrent Primary CNS Lymphoma (PCNSL): A Phase 2 Clinical Trial (S27. 009) J Dietrich, YB Chen, K Gallagher, J Jordan, D Forst, S Plotkin, K Lindell, ... Neurology 98 (18 Supplement), 2022 | | 2022 |
